The role of hormonal treatment in type 2 diabetes mellitus

References

• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2013;36(Suppl 1):S11–S66.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. 2011. Available from: http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition.
   Google Scholar
• Engelgau MM, Geiss LS, Saaddine JB. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140:945.
   PubMed Web of Science ®Google Scholar
• Imam K. Management and treatment of diabetes mellitus. Adv Exp Med Biol. 2012;771:356–380.
   Web of Science ®Google Scholar
• Ali MK, McKeever Bullard K, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999–2010. N Engl J Med. 2013;368(17):1613–1624.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. N Engl J Med. 2005;353:2643–2653.
   PubMed Web of Science ®Google Scholar
• White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the diabetes control and complications trial. Arch Ophthalmol. 2008;126:1707–1715.
   PubMed Web of Science ®Google Scholar
• Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A. 2010;107(37):16009–16012.
   Web of Science ®Google Scholar
• CDC. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States; 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
   Google Scholar
• Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case control analysis. Diabetes Care. 2008;31:2086–2091.
   PubMed Web of Science ®Google Scholar
• Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am. 1997;26:511–521.
   Web of Science ®Google Scholar
• Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab. 2002;87:4171–4176.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106.
   PubMed Web of Science ®Google Scholar
• Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349.
   PubMed Web of Science ®Google Scholar
• Lebowitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. 1998;6:132–145.
   Google Scholar
• Pospisilik JA, Stafford SG, Demuth HU. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDH Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes. 2003;51:2677–2683.
   Web of Science ®Google Scholar
• Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834–838.
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, Caria C, Davies M, Williams-Herman D. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564–2571.
   PubMed Web of Science ®Google Scholar
• Edward C, Chao DO. SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes. 2014;32:4–11.
   Google Scholar
• Nair S, Joseph F, Ewins D, Wilding J, Goenka N. From history to reality: sodium glucose co-transporter 2 inhibitors – a novel therapy for type 2 diabetes mellitus. Pract Diabetes Int. 2010;27:311–316.
   Google Scholar
• List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–657.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–579.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443.
   PubMed Web of Science ®Google Scholar
• Roumie CL, Hung AM, Greevy RA. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601–610.
   PubMed Web of Science ®Google Scholar
• Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95(11):4993–5002.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Turner RC. The UK prospective diabetes study: a review. Diabetes Care. 1998;21(Suppl 3):C35–C38.
   PubMedGoogle Scholar
• Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(10):938–953.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–1201.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJA. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspective pioglitAzone clinical trial in macrovascular events):a randomized controlled trial. Lancet. 2005;366:1279–1289.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290:486–494.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013;125(3):7–20.
   PubMed Web of Science ®Google Scholar
• Dziuba J, Alperin P, Racketa J, et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab. 2014;16(7):628–635.
   PubMed Web of Science ®Google Scholar
• Fisman EZ, Tenenbaum A, Motro M, Adler Y. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Herz. 2004;29(3):290–298.
   Web of Science ®Google Scholar
• Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting β-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:4206–4216.
   PubMed Web of Science ®Google Scholar
• UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44(11):1249–1258.
   Web of Science ®Google Scholar
• Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004;47(1):31–39.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention 2011. National Diabetes Fact Sheet; 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
   Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• AACE Comprehensive Diabetes. Management algorithm. Endocr Pract. 2013;19:327–336.
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963–1972.
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–B29.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Meneghini LF. Early insulin treatment in type 2 diabetes. Diabetes Care. 2009;32:S266–S269.
   PubMedGoogle Scholar
• Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78–86.
   Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26:518–524.
   Web of Science ®Google Scholar
• Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes Relat Metab Disord. 2002;26:S25–S30.
   PubMed Web of Science ®Google Scholar
• Larne AC, Pugh JA. Attitudes of primary care providers toward diabetes. Diabetes Care. 1998;21:1391–1396.
   Web of Science ®Google Scholar
• Nichols GA, Gandra SR, Chiou CF, Anthony MS, Alexander-Bridges M, Brown JB. Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. Curr Med Res Opin. 2010;26(1):9–15.
   PubMed Web of Science ®Google Scholar
• Unger RH, Grundy S. Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985;28:119–121.
   PubMed Web of Science ®Google Scholar
• Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008;29:351–366.
   PubMed Web of Science ®Google Scholar
• Gleason CE, Gonzalez M, Harmon JS, Robertson RP. Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab. 2000;279:E997–E1002.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222–234.
   PubMed Web of Science ®Google Scholar
• Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet. 2008;371:1753–1760.
   PubMed Web of Science ®Google Scholar
• Pfützner A, Lorra B, Abdollahnia MR, et al. The switch from sulfonylurea to preprandial short-acting insulin analog substitution has an immediate and comprehensive β-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2006;8:375–384.
   Web of Science ®Google Scholar
• Ritzel RA, Bulter PC. Physiology of glucose homeostasis and insulin secretion. In: Leahy JL, Cefalu WT, editors. Insulin Therapy. New York, NY: Marcel Dekker; 2002:61–72.
   Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–183.
   PubMed Web of Science ®Google Scholar
• Holleman F, Gale E. Nice insulins, pity about the evidence. Diabetologia. 2007;50:1783–1790.
   PubMed Web of Science ®Google Scholar
• Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care. 2010;33:281–283.
   Web of Science ®Google Scholar
• DeVries JH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique: response to Scholtz HE et al. Diabetologia. 2006;49:1125–1126.
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins: an assessment of the basal analogues based on isoglycemic clamp studies. Diabetes Obes Metab. 2007;9:648–659.
   PubMed Web of Science ®Google Scholar
• Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107–1112.
   PubMed Web of Science ®Google Scholar
• Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447–2452.
   PubMed Web of Science ®Google Scholar
• Ross SA, Zinman B, Campos RV, Strack T; Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med. 2001;24(6):292–298.
   PubMed Web of Science ®Google Scholar
• Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;18:CD005613.
   Web of Science ®Google Scholar
• Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758–767.
   PubMed Web of Science ®Google Scholar
• Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184–189.
   PubMed Web of Science ®Google Scholar
• Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab. 2010;12:772–779.
   PubMed Web of Science ®Google Scholar
• AACE. AACE comprehensive diabetes management. Endocr Pract. 2013;19(Suppl 1):1–48.
   Google Scholar
• Holman RR, Farmer AJ, Davies MJ, et al; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747.
   PubMed Web of Science ®Google Scholar
• Leahy JL. Insulin therapy in type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2012;41:119–144.
   PubMed Web of Science ®Google Scholar
• Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228–2234.
   PubMed Web of Science ®Google Scholar
• Young L, Buse JB. GLP-1 receptor agonists and basal insulin in type 2 diabetes. Lancet. 2014;384(9961):2180–2181.
   Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408–416.
   PubMed Web of Science ®Google Scholar
• Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25:542–548.
   PubMed Web of Science ®Google Scholar
• Mussig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring HU. Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism? Diabet Med. 2011;28:276–286.
   PubMed Web of Science ®Google Scholar
• Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes. Lancet. 2011;377:924–931.
   PubMed Web of Science ®Google Scholar
• Steiner S, Hompesch M, Pohl R, et al. A novel insulin formulation with a more rapid onset of action. Diabetologia. 2008;51:1602–1606.
   PubMed Web of Science ®Google Scholar
• Forst T, Pfützner A, Flacke F, et al. Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetes Care. 2010;33:116–120.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Rockville, MD: Food and Drug Administration; 2012.
   Google Scholar
• Heinemann L. Biosimilar insulins. Expert Opin Biol Ther. 2012;12:1009–1016.
   PubMed Web of Science ®Google Scholar
• Kramer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis. 2010;10:163–171.
   Google Scholar
• Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Endocrinol Metab. 2005;1:22–31.
   Google Scholar
• Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med. 2010;123(Suppl):S28–S37.
   Google Scholar
• DeFronzo RA, Ratner RE, Han J. Effects of Exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–1100.
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2005;27:2628–2635.
   Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol. 2012;7:214–228.
   PubMedGoogle Scholar
• Peyrot M, Rubin RR, Polonsky WH, Best JH. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Curr Med Res Opin. 2010;26:1047–1054.
   PubMed Web of Science ®Google Scholar
• Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care. 2009;32:1577–1582.
   PubMed Web of Science ®Google Scholar
• NIH conference. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115:956–961.
   Google Scholar
• Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK.Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes. 2003;52:1098–1103.
   PubMed Web of Science ®Google Scholar
• Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–2304.
   PubMed Web of Science ®Google Scholar
• Yi P, Park JS, Melton AD. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell. 2013;153(4):747–758.
   PubMed Web of Science ®Google Scholar
• Saisho Y, Butler AE, Manesso E, Butler PC. β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care. 2013;36(1):111–117.
   PubMed Web of Science ®Google Scholar
• Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology – emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006;6:318–327.
   Google Scholar
• Cummings BP. Leptin therapy in type 2 diabetes. Diabetes Obes Metab. 2013;15(7):607–612.
   Web of Science ®Google Scholar
• Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov. 2012;11(9):692–708.
   PubMed Web of Science ®Google Scholar
• Zorrilla EP, Iwasaki S, Moss JA, et al. Vaccination against weight gain. Proc Natl Acad Sci U S A. 2006;103(35):13226–13231.
   PubMed Web of Science ®Google Scholar
• Chen CY, Fujimiya M, Laviano A, Chang FY, Lin HC, Lee SD. Modulation of ingestive behavior and gastrointestinal motility by ghrelin in diabetic animals and humans. J Chin Med Assoc. 2010;73(5):225–229.
   Web of Science ®Google Scholar
• Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012;35(11):2148–2155.
   PubMed Web of Science ®Google Scholar
• Pagliuca FW, Millman JR, Gürtler M, et al. In vitro generation of functional human pancreatic β cells. Cell. 2014;159(2):428–439.
   PubMed Web of Science ®Google Scholar